Alirocumab in Post ACS Patients - Saving Lives at a Premium

Curr Cardiol Rev. 2022;18(1):e030621193814. doi: 10.2174/1573403X17666210603111158.
No abstract available

Keywords: Alirocumab; ODYSSEY outcome study; PCSK inhibitors; major adverse cardiac events; mortality.

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Anticholesteremic Agents*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Anticholesteremic Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • alirocumab